PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody weapon targets brain lymphoma in early trial
Disease control OngoingThis study tests a new drug called GNC-038 in people with a type of brain lymphoma that has returned or not responded to treatment. The main goals are to check the drug's safety and find the best dose. About 7 adults will take part, and researchers will also look for early signs …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 09:17 UTC
-
Could less chemo be better for brain lymphoma? major trial seeks answers
Disease control OngoingThis study tests whether a reduced-intensity chemotherapy regimen works better than the standard treatment for people newly diagnosed with primary CNS lymphoma, a rare brain cancer. About 331 adults aged 18 to 70 will receive either the standard MATRix protocol or a milder versio…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE3 • Sponsor: Klinikum Stuttgart • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs (acalabrutinib and durvalumab) for people with primary central nervous system lymphoma, a rare brain cancer. The study includes up to 25 patients whose cancer has returned or who cannot receive standard chemotherapy. The mai…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug cocktail shows promise for rare brain cancer
Disease control OngoingThis early-phase study tests a combination of the targeted drug ibrutinib with a chemotherapy regimen called TEDDI-R in people with primary CNS lymphoma, a rare brain cancer. The goal is to find the safest dose and see if the treatment can control the disease. About 68 adults wit…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:47 UTC